ZTlido® (lidocaine topical system) 1.8%

About Scilex Holding

Scilex Holding Company is dedicated to advancing non-opioid therapies for pain management, aiming to provide safer alternatives in the context of the national opioid epidemic. Its commercial portfolio includes ZTlido® (lidocaine topical system) 1.8% for post-herpetic neuralgia, and it has a pipeline featuring late-stage candidates like SP-102 (SEMDEXA™) for lumbar radicular pain. The company leverages a combination of commercial execution and clinical development to capture value in the large and growing pain therapeutics market.

Therapeutic Areas